Search

Your search keyword '"Orgill, Dennis P."' showing total 1,582 results
Start Over Author "Orgill, Dennis P."
1,582 results on '"Orgill, Dennis P."'

2. The long-term intercorrelation between post-burn pain, anxiety, and depression: a post hoc analysis of the “RE-ENERGIZE” double-blind, randomized, multicenter placebo-controlled trial

Author

Panayi, Adriana C., Heyland, Daren K., Stoppe, Christian, Jeschke, Marc G., Didzun, Oliver, Matar, Dany, Tapking, Christian, Palackic, Alen, Bliesener, Björn, Harhaus, Leila, Knoedler, Samuel, Haug, Valentin, Bigdeli, Amir K., Kneser, Ulrich, Orgill, Dennis P., and Hundeshagen, Gabriel

Published
2024
Full Text
View/download PDF

3. Evolution of Wound Healing

Author

Hamaguchi, Ryoko, Orgill, Dennis P., Khajuria, Ankur, editor, Hong, Joon Pio, editor, Neligan, Peter, editor, and Rohrich, Rod J., Foreword by

Published
2024
Full Text
View/download PDF

7. Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides

Author

Yu, Zizi, Vieyra-Garcia, Pablo, Benezeder, Theresa, Crouch, Jack D., Kim, Ira R., O’Malley, John T., Devlin, Phillip M., Gehad, Ahmed, Zhan, Qian, Gudjonsson, Johann E., Sarkar, Mrinal K., Kahlenberg, J. Michelle, Gerard, Nega, Teague, Jessica E., Kupper, Thomas S., LeBoeuf, Nicole R., Larocca, Cecilia, Tawa, Marianne, Pomahac, Bohdan, Talbot, Simon G., Orgill, Dennis P., Wolf, Peter, and Clark, Rachael A.

Published
2024
Full Text
View/download PDF

11. Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens

Author

Sampath, Ashwath Jonathan, Westerkam, Linnea L., Blum, Franklin R., Alhusayen, Raed, Bechara, Falk G., Caffrey, Julie, Carmona-Rivera, Carmelo, Chandran, Nisha Suyien, George, Ralph, Goldberg, Stephanie R., Gudjonsson, Johann E., Hansen, Scott L., Ingram, John R., Kirby, Brian, Marzano, Angelo Valerio, Matusiak, Łukasz, Orgill, Dennis P., Prens, Errol, van der Zee, Hessel H., van Straalen, Kelsey R., Zouboulis, Christos C., Byrd, Angel S., Frew, John W., Lowes, Michelle Anne, Naik, Haley B., Sokumbi, Olayemi, Mi, Qing-Sheng, Miedema, Jayson R., Googe, Paul B., and Sayed, Christopher J.

Published
2024
Full Text
View/download PDF

14. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management

Author

Alikhan, Ali, Sayed, Christopher, Alavi, Afsaneh, Alhusayen, Raed, Brassard, Alain, Burkhart, Craig, Crowell, Karen, Eisen, Daniel B, Gottlieb, Alice B, Hamzavi, Iltefat, Hazen, Paul G, Jaleel, Tara, Kimball, Alexa B, Kirby, Joslyn, Lowes, Michelle A, Micheletti, Robert, Miller, Angela, Naik, Haley B, Orgill, Dennis, and Poulin, Yves

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Management of diseases and conditions, 7.3 Management and decision making, Administration, Oral, Administration, Topical, Androgen Antagonists, Anti-Bacterial Agents, Canada, Evidence-Based Medicine, Female, Hidradenitis Suppurativa, Humans, Immunosuppressive Agents, Injections, Intralesional, Male, North America, Practice Guidelines as Topic, Prognosis, Publications, Risk Assessment, Treatment Outcome, United States, acne inversa, adalimumab, biomarkers, carbon dioxide laser, clindamycin, comorbidities, ertapenem, finasteride, guidelines, hidradenitis suppurativa, infliximab, laser, lifestyle modification, microbiome, Nd:YAG, oral contraceptive pills, rifampin, spironolactone, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Hidradenitis suppurativa is a severe and debilitating dermatologic disease. Clinical management is challenging and consists of both medical and surgical approaches, which must often be combined for best outcomes. Therapeutic approaches have evolved rapidly in the last decade and include the use of topical therapies, systemic antibiotics, hormonal therapies, and a wide range of immunomodulating medications. An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies and is reviewed in this second part of the management guidelines. A therapeutic algorithm informed by the evidence available at the time of the review is provided.

Published
2019

15. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part I: Diagnosis, evaluation, and the use of complementary and procedural management

Author

Alikhan, Ali, Sayed, Christopher, Alavi, Afsaneh, Alhusayen, Raed, Brassard, Alain, Burkhart, Craig, Crowell, Karen, Eisen, Daniel B, Gottlieb, Alice B, Hamzavi, Iltefat, Hazen, Paul G, Jaleel, Tara, Kimball, Alexa B, Kirby, Joslyn, Lowes, Michelle A, Micheletti, Robert, Miller, Angela, Naik, Haley B, Orgill, Dennis, and Poulin, Yves

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Anti-Bacterial Agents, Biological Products, Canada, Complementary Therapies, Dermatologic Surgical Procedures, Drug Therapy, Combination, Evidence-Based Medicine, Female, Hidradenitis Suppurativa, Humans, Immunosuppressive Agents, Male, North America, Practice Guidelines as Topic, Publishing, Risk Assessment, Severity of Illness Index, United States, acne inversa, adalimumab, biomarkers, carbon dioxide laser, clindamycin, comorbidities, ertapenem, finasteride, guidelines, hidradenitis suppurativa, infliximab, laser, lifestyle modification, microbiome, Nd:YAG, oral contraceptive pills, rifampin, spironolactone, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.

Published
2019

16. Anti-IL-6 eluting immunomodulatory biomaterials prolong skin allograft survival.

Author

Uehara, Mayuko, Li, Xiaofei, Sheikhi, Amir, Zandi, Nooshin, Walker, Brian, Saleh, Bahram, Banouni, Naima, Jiang, Liwei, Ordikhani, Farideh, Dai, Li, Yonar, Merve, Vohra, Ishaan, Kasinath, Vivek, Orgill, Dennis P, Khademhosseini, Ali, Annabi, Nasim, and Abdi, Reza

Subjects
Lymph Nodes, T-Lymphocytes, Animals, Mice, Inbred BALB C, Mice, Inbred C57BL, Swine, Fibrosis, Inflammation, Methacrylates, Gelatin, Interleukin-6, Immunologic Factors, Biocompatible Materials, Tissue Adhesives, Drug Delivery Systems, Skin Transplantation, Graft Survival, Female, Allografts, Drug Liberation, Bioengineering, Organ Transplantation, Transplantation, 2.1 Biological and endogenous factors, Skin, Inflammatory and Immune System, Biochemistry and Cell Biology, Other Physical Sciences
Abstract

A primary goal in the management of burn wounds is early wound closure. The use of skin allografts represents a lifesaving strategy for severe burn patients, but their ultimate rejection limits their potential efficacy and utility. IL-6 is a major pleiotropic cytokine which critically links innate and adaptive immune responses. Here, we devised anti-IL-6 receptor eluting gelatin methacryloyl (GelMA) biomaterials (GelMA/anti-IL-6), which were implanted at the interface between the wound beds and skin allografts. Our visible light crosslinked GelMA/anti-IL-6 immunomodulatory biomaterial (IMB) demonstrated a stable kinetic release profile of anti-IL-6. In addition, the incorporation of anti-IL-6 within the GelMA hydrogel had no effect on the mechanical properties of the hydrogels. Using a highly stringent skin transplant model, the GelMA/anti-IL-6 IMB almost doubled the survival of skin allografts. The use of GelMA/anti-IL-6 IMB was far superior to systemic anti-IL-6 receptor treatment in prolonging skin allograft survival. As compared to the untreated control group, skin from the GelMA/anti-IL-6 IMB group contained significantly fewer alloreactive T cells and macrophages. Interestingly, the environmental milieu of the draining lymph nodes (DLNs) of the mice implanted with the GelMA/anti-IL-6 IMB was also considerably less pro-inflammatory. The percentage of CD4+ IFNγ+ cells was much lower in the DLNs of the GelMA/anti-IL-6 IMB group in comparison to the GelMA group. These data highlight the importance of localized immune delivery in prolonging skin allograft survival and its potential utility in treating patients with severe burns.

Published
2019

21. Translational development of ABCB5+ dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers

Author

Kerstan, Andreas, Dieter, Kathrin, Niebergall-Roth, Elke, Klingele, Sabrina, Jünger, Michael, Hasslacher, Christoph, Daeschlein, Georg, Stemler, Lutz, Meyer-Pannwitt, Ulrich, Schubert, Kristin, Klausmann, Gerhard, Raab, Titus, Goebeler, Matthias, Kraft, Korinna, Esterlechner, Jasmina, Schröder, Hannes M., Sadeghi, Samar, Ballikaya, Seda, Gasser, Martin, Waaga-Gasser, Ana M., Murphy, George F., Orgill, Dennis P., Frank, Natasha Y., Ganss, Christoph, Scharffetter-Kochanek, Karin, Frank, Markus H., and Kluth, Mark A.

Published
2022
Full Text
View/download PDF

23. Frailty as a sequela of burn injury: a post hoc analysis of the "RE-ENERGIZE" multicenter randomized-controlled trial and the National Health Interview Survey.

Author

Panayi, Adriana C., Heyland, Daren K., Stoppe, Christian, Jeschke, Marc G., Knoedler, Samuel, Tapking, Christian, Didzun, Oliver, Haug, Valentin, Bigdeli, Amir K., Kneser, Ulrich, Orgill, Dennis P., and Hundeshagen, Gabriel

Subjects
BURN care units, FRAILTY, PROPENSITY score matching, HEALTH surveys, FATIGUE (Physiology), BURN patients
Abstract

Background: With advancements in burn treatment and intensive care leading to decreased mortality rates, a growing cohort of burn survivors is emerging. These individuals may be susceptible to frailty, characterized by reduced physiological reserve and increased vulnerability to stressors commonly associated with aging, which significantly complicates their recovery process. To date, no study has investigated burns as a potential risk factor for frailty. This study aimed to determine the short-term prevalence of frailty among burn survivors' months after injury and compare it with that of the general population. Methods: A post hoc analysis was conducted on the Randomized Trial of Enteral Glutamine to Minimize the Effects of Burn Injury (RE-ENERGIZE) trial, an international randomized-controlled trial involving 1200 burn injury patients with partial- or full-thickness burns. Participants who did not complete the 36-Item Short Form Health Survey (SF-36) questionnaire were excluded. Data for the general population were obtained from the 2022 National Health Interview Survey (NHIS). Frailty was assessed using the FRAIL (Fatigue, Resistance, Ambulation, Illness, Loss of weight) scale. Due to lack of data on loss of weight, for the purposes of this study, malnutrition was used as the fifth variable. Illness and malnutrition were based on admission data, while fatigue, resistance, and ambulation were determined from post-discharge responses to the SF-36. The burn cohort and general population groups were matched using propensity score matching and compared in terms of frailty status. Within the burn group, patients were divided into different subgroups based on their frailty status, and the differences in their (instrumental) activities of daily living (iADL and ADL) were compared. A multivariable analysis was performed within the burn cohort to identify factors predisposing to frailty as well as compromised iADL and ADL. Results: Out of the 1200 burn patients involved in the study, 600 completed the required questionnaires [follow-up time: (5.5 ± 2.3) months] and were matched to 1200 adults from the general population in the U.S. In comparison to the general population, burn patients exhibited a significantly higher likelihood of being pre-frail (42.3% vs. 19.8%, P < 0.0001), or frail (13.0% vs. 1.0%, P < 0.0001). When focusing on specific components, burn patients were more prone to experiencing fatigue (25.8% vs. 13.5%, P < 0.0001), limited resistance (34.0% vs. 2.7%, P < 0.0001), and restricted ambulation (41.8% vs. 3.8%, P < 0.0001). Conversely, the incidence rate of illness was observed to be higher in the general population (1.2% vs. 2.8%, P = 0.03), while no significant difference was detected regarding malnutrition (2.3% vs. 2.6%, P = 0.75). Furthermore, in comparison with robust burn patients, it was significantly more likely for pre-frail and frail patients to disclose compromise in ADL and iADL. The frail cohort reported the most pronounced limitation. Conclusions: Our findings suggest a higher incidence of post-discharge frailty among burn survivors in the short-term following injury. Burn survivors experience compromised fatigue, resistance, and ambulation, while rates of illness and malnutrition were lower or unchanged, respectively. These results underscore the critical need for early identification of frailty after a burn injury, with timely and comprehensive involvement of a multidisciplinary team including burn and pain specialists, community physicians, physiotherapists, nutritionists, and social workers. This collaborative effort can ensure holistic care to address and mitigate frailty in this patient population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. A multicentre clinical trial evaluating the outcomes of two application regimens of a unique keratin‐based graft in the treatment of Wagner grade one non‐healing diabetic foot ulcers.

Author

Armstrong, David G., Orgill, Dennis P., Galiano, Robert D., Glat, Paul M., Carter, Marissa J., Hanft, Jason, Surprenant, Maria, Isaac, Adam L., and Zelen, Charles M.

Subjects
TREATMENT of diabetic foot, WOUND healing, PERIPHERAL neuropathy, TRANSPLANTATION of organs, tissues, etc., RESEARCH funding, CLINICAL trials, TREATMENT effectiveness, RANDOMIZED controlled trials, DESCRIPTIVE statistics, TREATMENT duration, KERATINOCYTES, RESEARCH, PAIN, QUALITY of life, WOUND care, COMPARATIVE studies
Abstract

Diabetic foot complications that lead to lower extremity amputations pose a significant challenge to the entire global health system. In this multicentre clinical trial, 26 patients with chronic Wagner one diabetic foot ulcers (DFUs) were treated with a unique human keratin matrix graft applied either weekly or bi‐weekly, in addition to standard of care. The hypothesis was that bi‐weekly application would be similar to weekly application. The primary endpoint was complete wound closure by 12 weeks, and secondary endpoints included healing time, percent area reduction and weekly changes in peripheral neuropathy, pain and quality of life. In the intent‐to‐treat population, 77% (10/13) of DFUs treated with bi‐weekly application healed compared with 69% (9/13) treated with weekly application. The mean time to heal within 12 weeks in the bi‐weekly group was 61 days and in the weekly group was 54 days. The mean percent area reduction at 12 weeks was 94.7% in the bi‐weekly group compared with 84.8% in the weekly group. The number of grafts used in the bi‐weekly group was 3.9 compared with 6.2 in the weekly group. The results of this trial confirm our hypothesis that whether bi‐weekly or weekly application of the unique keratin matrix graft is used to treat nonhealing indolent DFUs, there is a high rate of complete healing. Based on these results, future studies should be conducted that further investigate the use of this novel human keratin matrix graft for the treatment of chronic DFUs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Allogeneic ABCB5+ Mesenchymal Stem Cells for Treatment-Refractory Chronic Venous Ulcers: A Phase I/IIa Clinical Trial

Author

Kerstan, Andreas, Dieter, Kathrin, Niebergall-Roth, Elke, Dachtler, Ann-Kathrin, Kraft, Korinna, Stücker, Markus, Daeschlein, Georg, Jünger, Michael, Görge, Tobias, Meyer-Pannwitt, Ulrich, Erfurt-Berge, Cornelia, von Engelhardt, Charlotte, Klare, Andreas, Pfeiffer, Christiane, Esterlechner, Jasmina, Schröder, Hannes M., Gasser, Martin, Waaga-Gasser, Ana M., Goebeler, Matthias, Ballikaya, Seda, Sadeghi, Samar, Murphy, George F., Orgill, Dennis P., Frank, Natasha Y., Ganss, Christoph, Scharffetter-Kochanek, Karin, Frank, Markus H., and Kluth, Mark A.

Published
2022
Full Text
View/download PDF

31. A purified reconstituted bilayer matrix shows improved outcomes in treatment of non‐healing diabetic foot ulcers when compared to the standard of care: Final results and analysis of a prospective, randomized, controlled, multi‐centre clinical trial

Author

Armstrong, David G., primary, Orgill, Dennis P., additional, Galiano, Robert D., additional, Glat, Paul M., additional, Kaufman, Jarrod P., additional, Carter, Marissa J., additional, DiDomenico, Lawrence A., additional, and Zelen, Charles M., additional

Published
2024
Full Text
View/download PDF

35. Racial Disparities in Surgical Outcomes after Mastectomy in 223,000 Female Breast Cancer Patients - A Retrospective Cohort Study

Author

Knoedler, Samuel, Kauke-Navarro, Martin, Knoedler, Leonard, Friedrich, Sarah, Matar, Dany Y, Diatta, Fortunay, Mookerjee, Vikram G, Ayyala, Haripriya, Wu, Mengfan, Kim, Bong-Sung; https://orcid.org/0000-0002-1022-3553, Machens, Hans-Guenther, Pomahac, Bohdan, Orgill, Dennis P, Broer, P Niclas, Panayi, Adriana C, Knoedler, Samuel, Kauke-Navarro, Martin, Knoedler, Leonard, Friedrich, Sarah, Matar, Dany Y, Diatta, Fortunay, Mookerjee, Vikram G, Ayyala, Haripriya, Wu, Mengfan, Kim, Bong-Sung; https://orcid.org/0000-0002-1022-3553, Machens, Hans-Guenther, Pomahac, Bohdan, Orgill, Dennis P, Broer, P Niclas, and Panayi, Adriana C

Abstract

BACKGROUND: Breast cancer mortality and treatment differ across racial groups. It remains unclear whether such disparities are also reflected in perioperative outcomes of breast cancer patients undergoing mastectomy. STUDY DESIGN: We reviewed the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database (2008-2021) to identify female patients who underwent mastectomy for oncological purposes. The outcomes were stratified by five racial groups (white, Black/African American, Asian, American Indian/Alaska Native, and Native Hawaiian/Pacific Islander) and included 30-day mortality, reoperation, readmission, surgical and medical complications, and non-home discharge. RESULTS: The study population included 222,947 patients, 68% (n=151,522) of whom were white, 11% (n=23,987) Black/African American, 5% (n=11,217) Asian, 0.5% (n=1,198) American Indian/Alaska Native, and 0.5% (n=1,018) Native Hawaiian/Pacific Islander. While 136,690 (61%) patients underwent partial mastectomy, 54,490 (24%) and 31,767 (14%) women received simple and radical mastectomy, respectively. Overall, adverse events occurred in 17, 222 (7.7%) patients, the largest portion of which were surgical complications (n=7,246; 3.3%). Multivariable analysis revealed that being of Asian race was protective against perioperative complications (OR=0.71; P<0.001), whereas American Indian/Alaska Native women were most vulnerable to the complication occurrence (OR=1.41; P<0.001). Black/African American patients had a significantly lower risk of medical (OR=0.59; P<0.001) and surgical complications (OR=0.60; P<0.001) after partial and radical mastectomy, respectively, their likelihood of readmission (OR=1.14; P=0.045) following partial mastectomy was significantly increased. CONCLUSION: We identified American Indian/Alaska Native women as particularly vulnerable to complications following mastectomy. Asian patients experienced the lowest rate of complications in the perioperative p

Published
2024

41. PPARγ agonist treatment reduces fibroadipose tissue in secondary lymphedema by exhausting fibroadipogenic PDGFRα+ mesenchymal cells

Author

Chen, Ziyu, primary, Ghavimi, Soheila Ali Akbari, additional, Wu, Mengfan, additional, McNamara, John, additional, Barreiro, Olga, additional, Maridas, David, additional, Kratchmarov, Radomir, additional, Siegel, Ashley, additional, Djeddi, Sarah, additional, Gutierrez-Arcelus, Maria, additional, Brennan, Patrick J., additional, Padera, Timothy P., additional, von Andrian, Ulrich, additional, Mehrara, Babak, additional, Greene, Arin K., additional, Kahn, C. Ronald, additional, Orgill, Dennis P., additional, Sinha, Indranil, additional, Rosen, Vicki, additional, and Agarwal, Shailesh, additional

Published
2023
Full Text
View/download PDF

42. Racial disparities in surgical outcomes after mastectomy in 223 000 female breast cancer patients: a retrospective cohort study

Author

Knoedler, Samuel, primary, Kauke-Navarro, Martin, additional, Knoedler, Leonard, additional, Friedrich, Sarah, additional, Matar, Dany Y., additional, Diatta, Fortunay, additional, Mookerjee, Vikram G., additional, Ayyala, Haripriya, additional, Wu, Mengfan, additional, Kim, Bong-Sung, additional, Machens, Hans-Guenther, additional, Pomahac, Bohdan, additional, Orgill, Dennis P., additional, Broer, P. Niclas, additional, and Panayi, Adriana C., additional

Published
2023
Full Text
View/download PDF

43. XENOGENIC IMPLANTATION OF HUMAN ADIPOSE MATRIX RESULTS IN ADIPOSE TISSUE FORMATION AND SURVIVAL IN MICE CONDITIONED WITH EXTERNAL VOLUME EXPANSION

Author

Panayi, Adriana C., primary, Wu, Mengfan, additional, Matar, Dany Y., additional, Yu, Zhen, additional, Karvar, Mehran, additional, Chen, Ziyu, additional, Ng, Brian, additional, Knoedler, Samuel, additional, Darwish, Oliver, additional, Agarwal, Shailesh, additional, and Orgill, Dennis P., additional

Published
2023
Full Text
View/download PDF

44. STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery

Author

Beamishaj, Bashashati, Mohammad, Millham, Frederick H., Orgill, Dennis P., Noureldin, Ashraf, Nixon, Iain James, Alsawadi, Abdulrahman, Bradley, Patrick J., Giordano, Salvatore, Laskin, Daniel M., Basu, Somprakas, Johnston, Maximilian, Muensterer, Oliver J., Mukherjee, Indraneil, Ngu, James Chi-Yong, Valmasoni, Michele, Pagano, Duilio, Vasudevan, Baskaran, Rosin, Richard David, McCaul, James Anthony, Albrecht, Jörg, Hoffman, Jerome R., Thorat, Mangesh A., Massarut, Samuele, Thoma, Achilles, Kirshtein, Boris, Afifi, Raafat Yahia, Farooq, Naheed, Challacombe, Ben, Pai, Prathamesh S., Perakath, Benjamin, Kadioglu, Huseyin, Aronson, Jeffrey K., Raveendran, Kandiah, Machado-Aranda, David, Klappenbach, Roberto, Healy, Donagh, Miguel, Diana, Leles, Claudio Rodrigues, Ather, M. Hammad, Agha, Riaz, Abdall-Razak, Ali, Crossley, Eleanor, Dowlut, Naeem, Iosifidis, Christos, and Mathew, Ginimol

Published
2019
Full Text
View/download PDF

45. Embryonic stem cell extracts improve wound healing in diabetic mice

Author

Loretelli, Cristian, Ben Nasr, Moufida, Giatsidis, Giorgio, Bassi, Roberto, Lancerotto, Luca, D’Addio, Francesca, Valderrama-Vasquez, Alessandro, Scherer, Saja Sandra, Salvatore, Luca, Madaghiele, Marta, Abdelsalam, Ahmed, Ippolito, Elio, Assi, Emma, Usuelli, Vera, El Essawy, Basset, Sannino, Alessandro, Pietramaggiori, Giorgio, Zuccotti, Gian Vincenzo, Orgill, Dennis Paul, and Fiorina, Paolo

Published
2020
Full Text
View/download PDF

48. In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials

Author

Tappenbeck, Nils, Schröder, Hannes M., Niebergall-Roth, Elke, Hassinger, Fathema, Dehio, Ulf, Dieter, Kathrin, Kraft, Korinna, Kerstan, Andreas, Esterlechner, Jasmina, Frank, Natasha Y., Scharffetter-Kochanek, Karin, Murphy, George F., Orgill, Dennis P., Beck, Joachim, Frank, Markus H., Ganss, Christoph, and Kluth, Mark A.

Published
2019
Full Text
View/download PDF

49. The SCARE 2018 statement: Updating consensus Surgical CAse REport (SCARE) guidelines

Author

Zhu, Hongyi, Alsawadi, Abdulrahman, Noureldin, Ashraf, Rao, Ashwini, Enam, Ather, Thoma, Achilleas, Bashashati, Mohammad, Vasudevan, Baskaran, Beamish, Andrew, Challacombe, Ben, De Wilde, Rudy Leon, Machado-Aranda, David, Laskin, Daniel, Muzumdar, Dattatraya, D'cruz, Anil, Manning, Todd, Healy, Donagh, Pagano, Duilio, Goel, Prabudh, Ranganathan, Priya, Pai, Prathamesh S., Raja, Shahzad, Ather, M. Hammad, kadioäžlu, Hüseyin, Nixon, Iain, Mukherjee, Indraneil, Gómez Rivas, Juan, Raveendran, Kandiah, Derbyshire, Laura, Valmasoni, Michele, Chalkoo, Mushtaq, Raison, Nicholas, Muensterer, Oliver, Bradley, Patrick, Coppola, Roberto, Afifi, Raafat, Rosin, David, Klappenbach, Roberto, Wynn, Rolf, Giordano, Salvatore, Basu, Somprakas, Surani, Salim, Suman, Paritosh, Thorat, Mangesh, Kasi, Veeru, Agha, Riaz A., Borrelli, Mimi R., Farwana, Reem, Koshy, Kiron, Fowler, Alexander J., and Orgill, Dennis P.

Published
2018
Full Text
View/download PDF

50. The PROCESS 2018 statement: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines

Author

Zhu, Hongyi, Alsawadi, Abdulrahman, Noureldin, Ashraf, Rao, Ashwini, Enam, Ather, Thoma, Achilleas, Bashashati, Mohammad, Vasudevan, Baskaran, Beamish, Andrew, Challacombe, Ben, De Wilde, Rudy Leon, Machado-Aranda, David, Laskin, Daniel, Muzumdar, Dattatraya, D'cruz, Anil, Manning, Todd, Healy, Donagh, Pagano, Duilio, Goel, Prabudh, Ranganathan, Priya, Pai, Prathamesh S., Raja, Shahzad, Ather, M. Hammad, kadioäžlu, Hüseyin, Nixon, Iain, Mukherjee, Indraneil, Gómez Rivas, Juan, Raveendran, Kandiah, Derbyshire, Laura, Valmasoni, Michele, Chalkoo, Mushtaq, Raison, Nicholas, Muensterer, Oliver, Bradley, Patrick, Coppola, Roberto, Afifi, Raafat, Rosin, David, Klappenbach, Roberto, Wynn, Rolf, Giordano, Salvatore, Basu, Somprakas, Surani, Salim, Suman, Paritosh, Thorat, Mangesh, Kasi, Veeru, Agha, Riaz A., Borrelli, Mimi R., Farwana, Reem, Koshy, Kiron, Fowler, Alexander J., and Orgill, Dennis P.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results